Figures & data
Figure 1 The flow chart of retrospective study for the influence of KDR genetic variation on the efficacy and safety of patients with chemotherapy refractory metastatic CRC receiving apatinib monotherapy.
Table 1 The Four Polymorphisms Included in This Study and the Preliminary Analysis Between Genotypes Status and Prognosis
Table 2 Baseline Characteristics of the 108 Patients with Metastatic CRC According to Genotype Status of rs2071559 Polymorphism
Figure 2 Waterfall plot for the best percentage change in target lesion size of the 108 patients with chemotherapy-refractory metastatic CRC according to KDR rs2071559 genotype status.
Figure 3 The MRI scan changes of target lesions in colorectal cancer patients with lung metastases after 4 cycles of apatinib treatment.
Figure 4 The progression-free survival and overall survival of the 108 patients with chemotherapy-refractory metastatic CRC.
Figure 5 The progression-free survival of the 108 patients with chemotherapy-refractory metastatic CRC according to KDR rs2071559 genotype status.
Figure 6 The overall survival of the 108 patients with chemotherapy-refractory metastatic CRC according to KDR rs2071559 genotype status.
Table 3 Overall Survival of the 108 Patients with Metastatic CRC According to Baseline Characteristics and Polymorphism in Univariate and Multivariate Analysis
Figure 7 The safety profile of patients with chemotherapy refractory metastatic CRC receiving apatinib monotherapy.
Figure 8 Relative mRNA expression level of KDR gene according to KDR rs2071559 genotype status.
